0000882104-20-000187.txt : 20201120 0000882104-20-000187.hdr.sgml : 20201120 20201120202202 ACCESSION NUMBER: 0000882104-20-000187 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201118 FILED AS OF DATE: 20201120 DATE AS OF CHANGE: 20201120 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bazaar Alan Lee CENTRAL INDEX KEY: 0001296974 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19756 FILM NUMBER: 201334079 MAIL ADDRESS: STREET 1: 9 BEDFORD ROAD CITY: KATONAH STATE: NY ZIP: 10536 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PDL BIOPHARMA, INC. CENTRAL INDEX KEY: 0000882104 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943023969 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 BUSINESS PHONE: 775-832-8500 MAIL ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 FORMER COMPANY: FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE DATE OF NAME CHANGE: 19930328 4 1 wf-form4_160592170507877.xml FORM 4 X0306 4 2020-11-18 0 0000882104 PDL BIOPHARMA, INC. PDLI 0001296974 Bazaar Alan Lee 932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451 1 0 0 0 Common stock 2020-11-18 4 M 0 37080 1.71 A 70515 D Common stock 2020-11-18 4 F 0 26642 2.38 D 43873 D Common stock 2020-11-20 4 S 0 33435 2.4227 D 10438 D Stock Option (right to buy) 1.71 2020-11-18 4 M 0 37080 1.71 D 2021-04-17 2030-04-17 Common stock 37080.0 0 D On May 21, 2020, the Company completed the distribution to its stockholders of its shares of common stock in Evofem Biosciences, Inc., which resulted in a $0.58 reduction to the exercise price of the stock option at such time pursuant to the Company's wind-down retention plan. On October 1, 2020, the Company completed the distribution to its stockholders of its shares of common stock in LENSAR, Inc., which resulted in a $0.78 reduction to the exercise price of the stock option at such time pursuant to the Company's wind-down retention plan. /s/ Nathan Kyrszak, Attorney-in-Fact for Alan Bazaar 2020-11-19